A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia

Cancer

Volumn 112, Issue 3, 2008, Pages 645-649

  Miettinen, Markku ^a   Kraszewska, Ewa ^b   Sobin, Leslie H ^a   Lasota, Jerzy ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Acute myeloid leukemia; Chronic myeloid leukemia; Gastrointestinal stromal tumor; KIT; Platelet derived growth factor receptor

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CALCULATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALE; MITOSIS RATE; MYELOID LEUKEMIA; MYELOMONOCYTIC LEUKEMIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SIGNAL TRANSDUCTION; TUMOR VOLUME; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; DATA INTERPRETATION, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INCIDENCE; INTESTINAL NEOPLASMS; LEUKEMIA, MYELOID; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 38749153233     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23216     Document Type: Article

References (29)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;43:1-12.
2. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population-based study in western Sweden. Cancer. 2005;103:821-829.
3. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
4. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-710.
5. Kitamura Y, Hirota S. Kit as human oncogenic tyrosine kinase. Cell Mol Life Sci. 2004;61:2924-2931.
6. Demetri G, van Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
7. Druker BJ. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother. 2003;4:963-971.
8. Miettinen M, Kopczynski J, Maklouf HR, et al. Gastrointestinal stromal tumors, intramural leiomyomas and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical and molecular genetic study of 167 cases. Am J Surg Pathol. 2003;27:625-641.
9. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29:52-68.
10. Miettinen M, Makhlouf HR, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical and molecular genetic study with a long-term follow-up prior to imatinib. Am J Surg Pathol. 2006;30:477-489.
11. Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG. Cancer registration. Principles and methods. IARC Scientific Pub. No. 95. Lyon, France: IARC; 1991.
12. Vandenbroucke JP. A shortcut method for calculating the 95 percent confidence interval of the standardized mortality ratio. Am J Epidemiol. 1982;115:303-304.
13. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British co-operative group. Br J Haematol. 1976;33:451-458.
14. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
15. Yoshioka K, Yamaguchi M, Kasamatsu Y, et al. Acute promyoelocytic leukemia following leiomyosarcoma of the jejunum. Arch Intern Med. 1997;137:1392-1393.
16. Herbers AH, Keuning JJ. Staging for CLL-type non-Hodgkin lymphoma reveals a gastrointestinal stromal tumor. Neth J Med. 2005;63:74-75.
17. Agaimy A, Wunsch P, Sobin LH, Lasota J, Miettinen M. Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol. 2006;23:120-129.
18. Antonescu CR, Viale A, Sarran L, et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res. 2004;10:3282-3290.
19. Subramanian S, West RB, Corless CL, et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene. 2004;23:7780-7790.
20. Prakash S, Sarran L, Socci N, et al. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol. 2005;27:179-187.
21. Miettinen M, Lasota J, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol. 2005;29:1373-1381.
22. Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res. 2005;11:1167-1173.
23. Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Hematologica. 2004;89:920-925.
24. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a cancer and leukemia group B study. J Clin Oncol. 2006;24:3904-3911.
25. Wang YY, Zhou GB, Yin T, et al. AML1-ETO and C-KIT mutation/ overexpression in the t(8;21) leukemia: implication in stepwise leukemiogenesis and response to Gleevec. Proc Natl Acad Sci USA. 2005;102:1104-1109.
26. Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107: 1791-1799.
27. Hartmann K, Wardelmann E, Ma Y, et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology. 2005; 129:1042-1046.
28. Corbacioglu S, Kilic M, Westhoff MA, Reinhardt D, Fulda S, Debatin KM. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood. 2006;108:3504-3513.
29. Bono P, Krause A, von Mehren M, et al. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood. 2004;103:2929-2935.